Overview

An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Status:
Enrolling by invitation

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

Extension study for subjects who participated in a previous Astex-sponsored clinical study of ASTX727 (including, but not limited to ASTX727-01, ASTX727-02, ASTX727-04).

Phase:

Phase 2

Details

Lead Sponsor:

Astex Pharmaceuticals, Inc.

Treatments:

Decitabine